Risk characterization approach enables safety comparisons between Xeljanz, TNF inhibitors
by Traci Bratton
Use of a risk characterization approach served as an indirect way to contextualize the safety profile of Xeljanz, a Janus kinase inhibitor, in patients with rheumatoid arthritis vs. the safety profile of tumor necrosis factor-alpha inhibitors, according to research.